AVANIR Pharmaceuticals (FRA:AV2B) FCF Margin % : -23.39% (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. AVANIR Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2014 was €-5.94 Mil. AVANIR Pharmaceuticals's Revenue for the three months ended in Sep. 2014 was €25.38 Mil. Therefore, AVANIR Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2014 was -23.39%.

As of today, AVANIR Pharmaceuticals's current FCF Yield % is 0.00%.

The historical rank and industry rank for AVANIR Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:AV2B' s FCF Margin % Range Over the Past 10 Years
Min: -44.56 Med: 0 Max: 0
Current: -44.56

FRA:AV2B's FCF Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.235 vs FRA:AV2B: -44.56

AVANIR Pharmaceuticals FCF Margin % Historical Data

The historical data trend for AVANIR Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals FCF Margin % Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

FCF Margin %

Get a 7-Day Free Trial

-829.43

-555.84

-141.66

-87.40

-44.96

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
FCF Margin %	Get a 7-Day Free Trial															-139.82	-41.28	-61.96	-57.02	-23.39

Competitive Comparison of AVANIR Pharmaceuticals's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVANIR Pharmaceuticals's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's FCF Margin % falls into.

AVANIR Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

AVANIR Pharmaceuticals's FCF Margin for the fiscal year that ended in Sep. 2014 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2014 )	/	Revenue (A: Sep. 2014 )
	=	-40.129	/	89.263
	=	-44.96 %

AVANIR Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2014 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2014 )	/	Revenue (Q: Sep. 2014 )
	=	-5.937	/	25.379
	=	-23.39 %

AVANIR Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » FCF Margin %

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines